Ocugen Expands Into Europe Ahead of Gene Therapy Filings

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene...

Ocugen’s Global Push Gains Shape as Investors Wait on Funding Vote and Phase 3 Data

Ocugen is trying to build an international business before its lead therapy has even cleared the clinic. That is a difficult order in biotech, and the market is treating it as such. The shares finished the latest session at EUR 0.7520, down 5.5 percent on the day. In the current trading day, they were quoted […]

Release - Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa - Channelchek

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen’s novel modifier gene therapy for the treatment of Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.

Ocugen Expands Into Europe Ahead of Gene Therapy Filings

MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) has established a European affiliate in Amsterdam and appointed former Moderna Netherlands executive Jolanda Crombach to lead it, positioning the Malvern biotechnology company …